Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

Anna Signor, Stefano Comai, Gianfranco Pasut, Franco Folli, Marco Gentilucci, Negar Gharavi, Sofia Raitsin, Thuy Van Nguyen, Marco Pappagallo, Andrea Mattarei, Paolo L. Manfredi, Sara De Martin

Open source

DOI
10.1002/bcp.70839
Published
2026-09-21
Container
British Journal of Clinical Pharmacology
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/bcp.70839,
  title = {Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants},
  author = {Anna Signor and Stefano Comai and Gianfranco Pasut and Franco Folli and Marco Gentilucci and Negar Gharavi and Sofia Raitsin and Thuy Van Nguyen and Marco Pappagallo and Andrea Mattarei and Paolo L. Manfredi and Sara De Martin},
  year = {2026},
  journal = {British Journal of Clinical Pharmacology},
  doi = {10.1002/bcp.70839},
  url = {https://doi.org/10.1002/bcp.70839}
}

RIS

TY  - JOUR
TI  - Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants
AU  - Anna Signor
AU  - Stefano Comai
AU  - Gianfranco Pasut
AU  - Franco Folli
AU  - Marco Gentilucci
AU  - Negar Gharavi
AU  - Sofia Raitsin
AU  - Thuy Van Nguyen
AU  - Marco Pappagallo
AU  - Andrea Mattarei
AU  - Paolo L. Manfredi
AU  - Sara De Martin
PY  - 2026
JO  - British Journal of Clinical Pharmacology
DO  - 10.1002/bcp.70839
UR  - https://doi.org/10.1002/bcp.70839
ER  - 

APA

Signor, A., Comai, S., Pasut, G., Folli, F., Gentilucci, M., Gharavi, N., Raitsin, S., Nguyen, T. V., Pappagallo, M., Mattarei, A., Manfredi, P. L., & Martin, S. D. (2026). Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70839

Source records